Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY Pre-Tax Margin
Income before tax as a percentage of revenue.
Bristol-Myers Squibb CompanyNYSE: BMY
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin widens to 31.5%
Pre-tax margin was 31.5% in Q2 FY2026, up 17.0 pp from a year earlier. On a trailing-twelve-month basis it was 24.2%, up 10.4 pp year over year. Over 3 fiscal years it widened by 2.6 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 19.4%
- Year-over-year change
- +36.7pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.4% | +36.7pp |
| FY2024 | 2024-12-31 | -17.3% | -36.1pp |
| FY2023 | 2023-12-31 | 18.8% | +2.0pp |
| FY2022 | 2022-12-31 | 16.7% | -0.7pp |
| FY2021 | 2021-12-31 | 17.5% | — |
Pre-Tax Margin vs competitors
How BMY compares with its peers on the latest reported figures
- BMY's LTM Jun 2026 pre-tax margin of 24.2% is the 4th highest of the 11 companies compared; the peer median is 18.6%.
- Its year-over-year change of +10.4 pp is the 3rd highest of 11, against a peer median of +0.6 pp.
- Over three fiscal years its change of +2.6 pp compares with a peer median of +7.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 42.2% | +10.5 pp | +15.6 pp | |
| LTM Jun 2026 | 27.9% | -0.4 pp | +13.5 pp | |
| LTM Jun 2026 | 27.0% | +5.7 pp | -3.5 pp | |
| LTM Jun 2026 | 24.2% | +10.4 pp | +2.6 pp | |
| LTM Sep 2026 | 21.3% | +1.6 pp | +15.5 pp | |
| LTM Sep 2026 | 19.4% | +16.6 pp | -12.4 pp | |
| LTM Sep 2026 | 17.9% | -16.3 pp | +10.4 pp | |
| LTM Jun 2026 | 17.8% | +3.2 pp | +3.5 pp | |
| LTM Jun 2026 | 9.0% | -21.1 pp | +4.7 pp | |
| LTM Jun 2026 | 6.6% | -9.9 pp | -22.3 pp | |
| LTM Jun 2026 | -6.4% | -31.4 pp | +12.0 pp | |
| Peer median (excluding BMY) | 18.6% | +0.6 pp | +7.5 pp | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 46.39B | 46.16B | 45.01B | 48.3B | 48.2B |
| Cost of Revenue | 9.94B | 10.14B | 10.69B | 13.97B | 13.94B |
| Gross Profit | 36.45B | 36.02B | 34.31B | 34.33B | 34.26B |
| Gross Margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Research & Development | 10.2B | 9.51B | 9.3B | 11.16B | 9.95B |
| Selling, General & Admin | 7.69B | 7.81B | 7.77B | 8.41B | 7.27B |
| Operating Expenses | 27.91B | 26.92B | 26.12B | 28.45B | 20.54B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| EBITDA | 20.12B | 19.22B | 19.37B | 3.17B | 15.23B |
| EBITDA Margin | 43.4% | 41.6% | 43.0% | 6.6% | 31.6% |
| Operating Income | 8.54B | 9.1B | 8.2B | 5.89B | 13.72B |
| Operating Margin | 18.4% | 19.7% | 18.2% | 12.2% | 28.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.33B | 1.23B | 1.17B | 1.95B | 1.89B |
| Other Income / Expenses | (439M) | (1.39B) | 245M | (14.27B) | (4.4B) |
| Income Before Tax | 8.1B | 7.71B | 8.44B | (8.38B) | 9.33B |
| Pre-Tax Margin | 17.5% | 16.7% | 18.8% | -17.3% | 19.4% |
| Income Tax Expense | 1.08B | 1.37B | 400M | 554M | 2.27B |
| Net Income | 6.99B | 6.33B | 8.03B | (8.95B) | 7.05B |
| Net Margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| EPS (Basic) | 3.15 | 2.97 | 3.88 | (4.41) | 3.46 |
| EPS (Diluted) | 3.12 | 2.95 | 3.86 | (4.41) | 3.45 |
| Weighted Avg Shares | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B |
| Weighted Avg Shares (Diluted) | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.